MK-8591B / Merck (MSD)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-8591B / Merck (MSD)
2020-003071-18: Dose Ranging, Switch Study of ISL and MK-8507 Once-Weekly

Not yet recruiting
2
140
Europe
Islatravir, MK-8507, MK-8591, MK-8507, Capsule, Tablet, Film-coated tablet, Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
HIV-1 infection, HIV-1 infection, Diseases [C] - Virus Diseases [C02]
 
 

Download Options